Related references
Note: Only part of the references are listed.Temozolomide induces activation of Wnt/β-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy
Vivek Singh Tomar et al.
CELL BIOLOGY AND TOXICOLOGY (2020)
Wnt/β-catenin signaling pathway induces autophagy-mediated temozolomide-resistance in human glioblastoma
Eun-Jin Yun et al.
CELL DEATH & DISEASE (2020)
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol
Paul Lesueur et al.
BMC CANCER (2019)
Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells
Graham MacLeod et al.
CELL REPORTS (2019)
DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas
Bernd Kaina et al.
DNA REPAIR (2019)
ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation
Luciana Rodrigues Gomes et al.
CELL DEATH & DISEASE (2019)
Genome-Wide CRISPR-Cas9 Screening Identifies NF-κB/E2F6 Responsible for EGFRvIII-Associated Temozolomide Resistance in Glioblastoma
Kai Huang et al.
ADVANCED SCIENCE (2019)
Nrf2 and SQSTM1/p62 jointly contribute to mesenchymal transition and invasion in glioblastoma
Petri Polonen et al.
ONCOGENE (2019)
The Regulation of NFE2L2 (NRF2) Signalling and Epithelial-to-Mesenchymal Transition in Age-Related Macular Degeneration Pathology
Juha M. T. Hyttinen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
A view on drug resistance in cancer
Neil Vasan et al.
NATURE (2019)
The balance between NRF2/GSH antioxidant mediated pathway and DNA repair modulates cisplatin resistance in lung cancer cells
Matheus Molina Silva et al.
SCIENTIFIC REPORTS (2019)
Current promising treatment strategy for glioblastoma multiform: A review
Sanjib Bahadur et al.
ONCOLOGY REVIEWS (2019)
CRISPR/Cas9 library screening for drug target discovery
Morito Kurata et al.
JOURNAL OF HUMAN GENETICS (2018)
Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis
Zhongling Zhu et al.
JOURNAL OF NEUROCHEMISTRY (2018)
HDAC6 inhibition induces glioma stem cells differentiation and enhances cellular radiation sensitivity through the SHH/Gli1 signaling pathway
Wei Yang et al.
CANCER LETTERS (2018)
A highlight on Sonic hedgehog pathway
Gabriela Basile Carballo et al.
CELL COMMUNICATION AND SIGNALING (2018)
Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment
Xiao-Tang Kong et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Current state of immunotherapy for glioblastoma
Michael Lim et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
Stephen J. Pettitt et al.
NATURE COMMUNICATIONS (2018)
Investigating the role of Hedgehog/GLI1 signaling in glioblastoma cell response to temozolomide
Jilian R. Melamed et al.
Oncotarget (2018)
Transcriptional Regulation by Nrf2
Claudia Tonelli et al.
ANTIOXIDANTS & REDOX SIGNALING (2018)
The role of the Hedgehog signaling pathway in cancer: A comprehensive review
Ana Marija Skoda et al.
BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES (2018)
Interrelationship of canonical and non-canonical Wnt signalling pathways in chronic metabolic diseases
Ian Ackers et al.
DIABETES & VASCULAR DISEASE RESEARCH (2018)
Cornerstones of CRISPR-Cas in drug discovery and therapy
Christof Fellmann et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
High OCT4A levels drive tumorigenicity and metastatic potential of medulloblastoma cells
Patricia Benites Goncalves da Silva et al.
ONCOTARGET (2017)
Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma
Ke Wang et al.
CANCER CELL INTERNATIONAL (2017)
Transcription factor NFE2L2/NRF2 is a regulator of macroautophagy genes
Marta Pajares et al.
AUTOPHAGY (2016)
Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression
Claudius Klein et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Akt and β-catenin contribute to TMZ resistance and EMT of MGMT negative malignant glioma cell line
Guo-zhong Yi et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2016)
NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells
Clarissa Ribeiro Reily Rocha et al.
ONCOTARGET (2016)
Temozolomide resistance in glioblastoma multiforme
Sang Y. Lee
GENES & DISEASES (2016)
Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide
Jose L. McFaline-Figueroa et al.
CANCER RESEARCH (2015)
p62 links autophagy and Nrf2 signaling
Tao Jiang et al.
FREE RADICAL BIOLOGY AND MEDICINE (2015)
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
Silvana Konermann et al.
NATURE (2015)
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance
Malin Wickstrom et al.
NATURE COMMUNICATIONS (2015)
Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR
Wei Li et al.
GENOME BIOLOGY (2015)
The circadian clock regulates rhythmic activation of the NRF2/glutathione-mediated antioxidant defense pathway to modulate pulmonary fibrosis
Vanja Pekovic-Vaughan et al.
GENES & DEVELOPMENT (2014)
Phase locking and multiple oscillating attractors for the coupled mammalian clock and cell cycle
Celine Feillet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
Ophir Shalem et al.
SCIENCE (2014)
Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo
C. R. R. Rocha et al.
CELL DEATH & DISEASE (2014)
Role of Nrf2 in Oxidative Stress and Toxicity
Qiang Ma
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 53, 2013 (2013)
The emerging role of the Nrf2-Keap1 signaling pathway in cancer
Melba C. Jaramillo et al.
GENES & DEVELOPMENT (2013)
CLCA2, a target of the p53 family, negatively regulates cancer cell migration and invasion
Yasushi Sasaki et al.
CANCER BIOLOGY & THERAPY (2012)
Molecular mechanisms of temozolomide resistance in glioblastoma multiforme
Tor-Christian Aase Johannessen et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
Gene Overexpression: Uses, Mechanisms, and Interpretation
Gregory Prelich
GENETICS (2012)
NRF2 and cancer: the good, the bad and the importance of context
Michael B. Sporn et al.
NATURE REVIEWS CANCER (2012)
Inhibition of Sonic Hedgehog and Notch Pathways Enhances Sensitivity of CD133(+) Glioma Stem Cells to Temozolomide Therapy
Ilya V. Ulasov et al.
MOLECULAR MEDICINE (2011)
Temozolomide: Mechanisms of Action, Repair and Resistance
Jihong Zhang et al.
Current Molecular Pharmacology (2011)
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
R. Stupp et al.
ANNALS OF ONCOLOGY (2010)
Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application
Aimee L. Jackson et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
hCLCA2 Is a p53-Inducible Inhibitor of Breast Cancer Cell Proliferation
Vijay Walia et al.
CANCER RESEARCH (2009)
Circadian oscillation of nucleotide excision repair in mammalian brain
Tae-Hong Kang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Malignant gliomas in adults
Patrick Y. Wen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
CLCA2 tumour suppressor gene in 1p31 is epigenetically regulated in breast cancer
XR Li et al.
ONCOGENE (2004)
Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients
S Ostermann et al.
CLINICAL CANCER RESEARCH (2004)
Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates
M Patel et al.
JOURNAL OF NEURO-ONCOLOGY (2003)
Share Paper
